Skip to NavigationSkip to content

EpiCast Report: Generalized Anxiety Disorder - Epidemiology Forecast to 2024 - ref #GB000052

EpiCast Report: Generalized Anxiety Disorder - Epidemiology Forecast to 2024

GAD is a common mental illness that is characterized by persistent and unrelenting worrying about everyday things such as personal finances, health, family, and work. GAD can be accompanied by one or all of the following physical symptoms: headache, fatigue, restlessness, edginess, and increased irritability. GAD is only diagnosed if the patient’s worrying and anxiety present most days out of a week for at least six months in combination with one or more of the physical symptoms. The diagnosis of GAD must also be shown not to be directly related to any substance abuse disorder or general medical condition; it must not occur exclusively during an episodic mood disorder, psychotic disorder, or pervasive developmental disorder.

GlobalData epidemiologists forecast that the 12-month total prevalent cases of GAD in the 8MM will grow by 4.8% from 13,688,954 cases in 2014 to 14,349,464 in 2024 and lifetime total prevalence will grow by 4.8% from 24,594,259 cases in 2014 to 25,770,599 in 2024. GlobalData epidemiologists predict that GAD will affect more women than men with 69.35% of 12-month GAD and 66.04% of lifetime GAD found in women in 2014. GlobalData epidemiologists forecast that the prevalence of 12-month and lifetime GAD peaks in the age group 50–59 years, which contributed 23.57% of 12-month GAD and 23.54% of lifetime GAD in the 8MM in 2014.

GlobalData’s epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of GAD in the 8MM during 2014–2024. GlobalData’s epidemiological forecast for the 12-month and lifetime total prevalent cases of GAD in the 8MM is supported by epidemiological data from country-specific studies, when available, which are nationally representative of the entire population of the respective market. This forecast is further strengthened by the use of uniform diagnostic criteria and methodology across each study that was included in the forecast. All countries for which data was found used the DSM-IV diagnostic criteria as well as the CIDI to estimate the total prevalence of GAD in each country. Each study used also presented a total prevalence rather than diagnosed, which gives a better estimate of the true burden of the disease as it will catch the undiagnosed cases of the disease.


- The Generalized Anxiety Disorder (GAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for GAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast of the one-year and lifetime prevalent cases of GAD segmented by sex, and age (in five-year increments beginning at 18 years and ending at =85 years) in these markets.
- The GAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The GAD EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global GAD market.
- Quantify patient populations in the global GAD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for GAD therapeutics in each of the markets covered.

Publisher: GlobalData
Publication date: October 2015

Price: £ 2,632.70

You need to agree to the Terms and Conditions before placing your order

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches